Stimulates phagocytosis by macrophages and neutrophils via NRP1 binding.
Reference facts
- Also known as
- Threonyl-Lysyl-Prolyl-Arginine, TKPR
- Category
- Immune Modulator
- Mechanism of action
- Stimulates phagocytosis by macrophages and neutrophils via NRP1 binding.
- Targets
- Neuropilin-1, Macrophage receptors
- Indications under research or approved
- Research — immunodeficiency, parasitic infections
- Regulatory status (reference entry)
- Not FDA-approved
- Half-life
- Minutes
- Sequence
- TKPR
- Sequence notes
- Tetrapeptide naturally cleaved from the Fc region of IgG (heavy chain residues 289-292).
- Molecular weight (Da)
- 501
- First reported
- 1970
- Origin
- Discovered by Victor Najjar at Tufts University.
Primary References
Explore research articles about Tuftsin
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.